Ongoing Cancer R&D Efforts at Tosk, Inc.

Tosk pic

Brian Frenzel is an accomplished private investor and serial entrepreneur who has excelled in the life sciences industry. Over the course of a career spanning more than 30 years, Brian Frenzel has successfully led a number of companies and now works with Tosk, Inc., SanBio Co. Ltd., and AnVent Enterprises.

Tosk, Inc. is a drug discovery and development company committed to improving outcomes for patients suffering from the painful and debilitating side effects of widely-used cancer therapies and to enhance treatment options for patients who have not benefited from therapy. Tosk has two patented drugs in development, TK-90 for mucositis side effect reduction and TK-39 for cardiotoxicity side effect reduction, and has two other drug discovery programs underway. Tosk calls them CompanionTM drugs because they are designed to be administered alongside existing therapies.

The Company’s other initiatives include TK-88, which is intended to selectively block the adverse side effects of platinum-based drugs such as carboplatin, cisplatin, and oxaliplatin, and TK-kRAS which targets the human kRAS oncogene. Platinum drugs are effective, front line therapies for ovarian, breast, cervical, lung, head and neck, endometrial, and esophageal cancers which, unfortunately, also cause kidney damage, peripheral nerve damage, and hearing loss.

Tosk’s mutant kRAS gene initiative focuses on blocking the effects of this important cancer growth promoter. Also, according to the US National Cancer Institute, an estimated 40 percent of cancer patients worldwide carry an autogenic kRAS gene that effectively negates the efficacy of EGFR-inhibitor cancer therapies, such as Erbitux® and Vectibix®, to fight the disease. A kRAS product could both prove effective in treating kRAS positive cancers, including 90% of pancreatic and 45% of colon cancers, as well as making EGFR inhibitors effective in patients who currently do not benefit from treatment.


Brian Frenzel: SanBio, Inc. – Improving the Lives of Patients with Neurological Disorders

A successful investor and life sciences entrepreneur, Brian Frenzel serves on the Board of Directors of SanBio, Inc., a regenerative medicine company.

Advances in medical technology have improved the quality of life and life expectancy for sufferers of neurodegenerative diseases such as Parkinson’s disease, multiple sclerosis, and spinal cord injury, as well as for patients who have had cerebral strokes. SanBio, Inc., in Mountain View, California, develops new therapies to help patients with these conditions to recover function and lead more comfortable lives. These therapies are designed to repair and regenerate damaged neuronal cells and tissues with the objective of reversing neurological damage and restoring normal function.

The core component of SanBio’s technology is the use of bone marrow stromal cells harvested from donors. When these cells are genetically manipulated and delivered to damaged tissue, they stimulate recovery. An important advantage of using donor bone marrow cells is that they are readily available and the cells from a single donor can be multiplied in cell culture to treat thousands of patients.

SanBio is developing products to treat cerebral stroke, spinal cord injury, Parkinson’s disease, multiple sclerosis, and traumatic brain injury. San Bio’s most advanced product, SB623, is undergoing human clinical trials in the United States to improve function in cerebral stroke patients.